Blog Archive
-
▼
2008
(233)
-
▼
January
(13)
- Medtronic, FDA Approval of CGMS iPro Continuous G...
- Arena Pharmaceuticals, APD668, Glucose-Dependent I...
- Daiichi Sankyo's Welchol, FDA Approval to Reduce B...
- Tissera , Curative Effect of Its Transplantation T...
- Incyte, HM74a agonist program for type 2 diabetes
- Echo Therapeutics, Clinical Study of Its Symphony ...
- DexCom, Joint Development Agreement with Animas Co...
- BodyTel, GlucoTel Technical Files for CE Certifica...
- Insulet and DexCom , Development Agreement
- VIVUS , Extension Study with Qnexa for Diabetes
- DiObex, Patent for the Prevention of Insulin-Induc...
- DIAMYD, PHASE III TRIAL WITH DIABETES VACCINE
- Adolor , Phase 2a Study of Delta Agonist ADL5859 i...
-
▼
January
(13)
Friday, January 11, 2008
Insulet and DexCom , Development Agreement
January 7, 2008 - Insulet Corporation (NASDAQ: PODD), the leader in wearable insulin pump technology with its OmniPod Insulin Management System, and DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced they have signed a development agreement to integrate DexCom's continuous glucose monitoring technology into the wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In addition to programming the patient's insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom's wearable sensor transmitter... DexCom's Press Release - Insulet's Press Release -
Libellés :
Blood Glucose Monitoring,
DexCom,
Insulet,
Insulin